BioCryst Crushes It on Rare Immune Disorder Drug Trial

Health and Healthcare

Published: May 27, 2014 10:50 am

Last Updated: April 27, 2020 5:40 pm

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) broke higher Tuesday morning, following the company’s announcement that its oral drug for hereditary angioedema (HAE) met the primary efficacy endpoint, several secondary endpoints and all other objectives established for its Phase 2a clinical trial. HAE is a rare, severely debilitating and potentially fatal genetic condition that occurs in about one in 10,000 to one in 50,000 people.

BioCryst’s treatment, BCX4161, is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with HAE. The drug suppresses the body’s production of bradykinin, which is a cause of acute swelling attacks in HAE sufferers.

BioCryst has been on something of a tear over the past 12 months. The share price is up more than 460%, and the stock reached its 52-week high shortly after the announcement in early March of a successful Phase 1 clinical trial of BCX4161.

Shares were up more than 11%, after rising as much as 20% earlier Tuesday morning. The stock was trading at $10.07 a half-hour after the open. The 52-week range is $1.42 to $13.33.

ALSO READ: Why You Buy Big Pharma If the Market Crashes

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!